Chronic lymphocytic leukemia clinical staging
|
Chronic lymphocytic leukemia Microchapters |
|
Differentiating Chronic lymphocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic lymphocytic leukemia clinical staging On the Web |
|
American Roentgen Ray Society Images of Chronic lymphocytic leukemia clinical staging |
|
Directions to Hospitals Treating Chronic lymphocytic leukemia |
|
Risk calculators and risk factors for Chronic lymphocytic leukemia clinical staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Clinical staging
Staging is done with the Rai staging system and the Binet classification (see details[1]).
Rai staging system
| Stage 0 | Absolute lymphocytosis (>15,000/mm3) without adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia. |
| Stage 1 | Absolute lymphocytosis with lymphadenopathy without hepatosplenomegaly, anemia, or thrombocytopenia. |
| Stage 2 | Absolute lymphocytosis with either hepatomegaly or splenomegaly with or without lymphadenopathy. |
| Stage 3 | Absolute lymphocytosis and anemia (hemoglobin <11 g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly. |
| Stage 4 | Absolute lymphocytosis and thrombocytopenia (<100,000/mm3) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anemia. |
Binet Classification
| Clinical stage A | No underlying causes |
| Clinical stage B | No underlying causes |
| Clinical stage C | No underlying causes |
Gene mutation status
Recent publications suggest that two[2] or three[3] prognostic groups of CLL exist based on the maturational state of the cell. This distinction is based on the maturity of the lymphocytes as discerned by the immunoglobulin variable-region heavy chain (IgVH) gene mutation status.[4] High risk patients have an immature cell pattern with few mutations in the DNA in the IgVH antibody gene region whereas low risk patients show considerable mutations of the DNA in the antibody gene region indicating mature lymphocytes.
Since assessment of the IgVH antibody DNA changes is difficult to perform, the presence of either cluster of differentiation 38 (CD38) or Z-chain–associated protein kinase-70 (ZAP-70) may be surrogate markers of high risk subtype of CLL.[4] Their expression correlates with a more immature cellular state and a more rapid disease course. Unmutated IGVH survive worse than mutated and are associated with aggressive CLL. The ZAP70 (AKA Zeta-Associated Protein) presence on the CLL cell correlates with unmutated immunoglobulin genes and a poor prognosis. Conversely, its absence indicates the presence of mutated genes and a good clinical outcome. Patients positive for ZAP70 have a CLL more aggressive in nature and more refractory to treatment. They are more likely to evolve to more unfavorable cytogenetic abnormalitites.
Fluorescence in situ hybridization (FISH)
In addition to the maturational state, the prognosis of patients with CLL is dependent on the genetic changes within the neoplastic cell population. These genetic changes can be identified by fluorescent probes to chromosomal parts using a technique referred to as fluorescent in situ hybridization (FISH).[4] Compared with fluorescence in-situ hybridization (FISH), conventional metaphase cytogenetics play ONLY a MINOR prognostic role in CLL, so far, due to technical problems resulting from a limited proliferation of CLL cells in-vitro. Therefore conventional cytogenetics may define subgroups with a high risk of progression. FISH can be done (in CLL) on dividing and non-dividing cells. FISH doesn't tell about IgVH mutations nor does it define the presence of trisomy either. FISH is useful as long as there are CLL cells to test; you can't do it in a complete response (CR).The application of FISH to study interphase nuclei gives important prognostic information with B-cell CLL, especially for patients with 11q-, trisomy 12, 13q- and 17q-. The procedure of FISH involves cell cultures which are prepared after metaphase and prometaphase chromosomes are fixed to a glass slide. A DNA probe is then hybridized onto the chromosome; the probe is labeled with fluorochrome which can be detected with fluorescent microscopy. FISH can be done on dividing and non-dividing cells. Inversions will be missed as probes detect sequences not precise locations. Small mutations, such as small deletions and insertions, will also be missed. FISH is a cytogenetic technology that looks at 200-500 blood cells (obtained with a bone marrow biopsy). Because of the small size it is not as sensitive as PCR. (PCR has extreme sensitivity as well as being quite specific). PCR amplifies a fragment of DNA. It is at least 2-3 logs more sensitive than cytogenetic technology like FISH. PCR measurement requires a sample blood draw which is less invasive and intense than a bone marrow biopsy (with FISH). Four main genetic aberrations are recognized in CLL cells that have a major impact on disease behavior.
- Deletions of part of the short arm of chromosome 17 (del 17p13) which target the cell cycle regulating protein p53 (a tumore suppressor gene) are particularly deleterious. Patients with this abnormality have significantly short interval before they require therapy and a shorter survival. This abnormality is found in 5-10% of patients with CLL.
- Deletions of the long arm on chromosome 11 (del 11q22-q23) are also unfavorable although not to the degree seen with del 17p. The abnormality targets the ATM gene and occurs infrequently in CLL (5-10%).
- Trisomy 12, an additional chromosome 12, is a relatively frequent finding occurring in 20-25% of patients and imparts an intermediate prognosis. It has a higher frequency of DNA aneuploidy.
- Deletion of the long arm of chromosome 13 (del 13q14) is the most common abnormality in CLL with roughly 50% of patients with cells containing this defect. These patients (along with those of normal karyotype) have the best prognosis and most will live many years, even decades, without the need for therapy. The gene targeted by this deletion is a segment that likely produces small inhibitory RNA molecules that affect expression of important death inhibiting genes.
The presence of 17p- typifies cells that are resistant to fludarabine, alkylators and rituxumab. 11q- portends a decreased RR to fludrabine as well as an early relapse after bone marrow transplant (BMT). Both the 17p- and the 11q- have a decreased progression-free survival (PFS) and overall survival (OS).
References
- ↑ National Cancer Institute. "Chronic Lymphocytic Leukemia (PDQ®) Treatment: Stage Information". Retrieved 2007-09-04.
- ↑ Rosenwald A, Alizadeh AA, Widhopf G; et al. (2001). "Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia". J. Exp. Med. 194 (11): 1639–47. PMID 11733578.
- ↑ Ghia P, Guida G, Stella S; et al. (2003). "The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression". Blood. 101 (4): 1262–9. doi:10.1182/blood-2002-06-1801. PMID 12406914.
- ↑ 4.0 4.1 4.2 Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE (2006). "Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia". Ann. Intern. Med. 145 (6): 435–47. PMID 16983131.